{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:09:41Z","timestamp":1793214581171,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T00:00:00Z","timestamp":1675382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) is a group of rare and highly heterogeneous renal cell carcinoma (RCC). The translocation involving TFE3 and different fusion partners lead to overexpression of the chimeric protein. The purpose of this study is to explore the clinicopathological features of Xp11.2 tRCC with four common fusion subtypes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We screened out 40 Xp11.2 tRCC patients from January 2007 to August 2021 in our institution. The diagnosis was initially confirmed by TFE3 immunohistochemistry (IHC) and fluorescence <jats:italic>in situ<\/jats:italic> hybridization (FISH) assay and their fusion partners were verified by RNA sequencing. Then the 40 cases were divided into two groups (DBHS family and non-DBHS family group) and a clinical comparison among the four common fusion subtypes was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among the 40 cases, 11 cases with SFPQ-TFE3 gene fusion and 7 cases with NONO-TFE3 gene fusion were classified in DBHS group, the remaining cases with ASPL-TFE3 (11 cases) or PRCC-TFE3 (11 cases) gene fusion were classified in non-DBHS group. Lymph node (LN) metastasis (P=0.027) and distant metastasis (P=0.009) were more common seen in non-DBHS family group than DBHS family group and cases in DBHS family group have better progressive-free survival (PFS) (P=0.02). In addition, ASPL-TFE3 fusion was associated with worse outcome (P=0.03) while NONO-TFE3 fusion (P=0.04) predicted a better prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Different fusion partner genes may play a functional role in various morphology, molecular and biological features of Xp11.2 tRCCs. The impact of fusion partners on clinical characteristics of Xp11.2 tRCCs deserves further exploration.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2023.1116648","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T05:05:24Z","timestamp":1675400724000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical and pathological heterogeneity of four common fusion subtypes in Xp11.2 translocation renal cell carcinoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Wei","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Pu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and Male genital organs-part a: Renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.162","article-title":"Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers","volume":"11","author":"Kauffman","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9440(10)61684-7","article-title":"Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents","volume":"159","author":"Argani","year":"2001","journal-title":"Am J Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200212000-00003","article-title":"PRCC-TFE3 renal carcinomas: morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21)","volume":"26","author":"Argani","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200306000-00005","article-title":"Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay","volume":"27","author":"Argani","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000835","article-title":"RBM10-TFE3 renal cell carcinoma: A potential diagnostic pitfall due to cryptic intrachromosomal Xp11.2 inversion resulting in false-negative TFE3 FISH","volume":"41","author":"Argani","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000631","article-title":"TFE3-fusion variant analysis defines specific clinicopathologic associations among Xp11 translocation cancers","volume":"40","author":"Argani","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201394","article-title":"Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma","volume":"15","author":"Clark","year":"1997","journal-title":"Oncogene"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/his.13167","article-title":"Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas","volume":"70","author":"Classe","year":"2017","journal-title":"Histopathology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22261","article-title":"Identification of a novel PARP14-TFE3 gene fusion from 10-year-old FFPE tissue by RNA-seq","volume":"54","author":"Huang","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3036","article-title":"Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes","volume":"20","author":"Malouf","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.1038\/s41467-021-25618-z","article-title":"Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma","volume":"12","author":"Sun","year":"2021","journal-title":"Nat Commun"},{"key":"B13","year":""},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.208","article-title":"Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage","volume":"27","author":"Ellis","year":"2014","journal-title":"Mod Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1093\/nar\/gkw271","article-title":"NONO and PSPC1: a multipurpose molecular scaffold","volume":"44","author":"Knott","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03033-4","article-title":"IGFBP-3 interacts with NONO and SFPQ in PARP-dependent DNA damage repair in triple-negative breast cancer","volume":"76","author":"de Silva","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15141","article-title":"NONO and tumorigenesis: More than splicing","volume":"24","author":"Feng","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41467-019-08863-1","article-title":"SFPQ and NONO suppress RNA:DNA-hybrid-related telomere instability","volume":"10","author":"Petti","year":"2019","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2016.204","article-title":"Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement","volume":"30","author":"Xia","year":"2017","journal-title":"Mod Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.241304198","article-title":"Impairment of MAD2B-PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas","volume":"98","author":"Weterman","year":"2001","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000873","article-title":"Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article","volume":"94","author":"Chen","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185337","article-title":"PRCC-TFE3 dual-fusion FISH assay: A new method for identifying PRCC-TFE3 renal cell carcinoma in paraffin-embedded tissue","volume":"12","author":"Xiong","year":"2017","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.169","article-title":"Molecular heterogeneity of TFE3 activation in renal cell carcinomas","volume":"25","author":"Macher-Goeppinger","year":"2012","journal-title":"Mod Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3825","article-title":"Genomic heterogeneity of translocation renal cell carcinoma","volume":"19","author":"Malouf","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318031ffff","article-title":"Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum","volume":"31","author":"Argani","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.14670\/HH-18-159","article-title":"MiT family translocation renal cell carcinomas: A 15th anniversary update","volume":"35","author":"Gandhi","year":"2020","journal-title":"Histol Histopathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.humpath.2017.02.022","article-title":"SFPQ\/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion","volume":"63","author":"Wang","year":"2017","journal-title":"Hum Pathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.2017020558","article-title":"Xp11 translocation renal cell carcinoma and the mesenchymal counterparts: An evolving concept with novel insights on clinicopathologic features, prognosis, treatment, and classification","volume":"22","author":"Wang","year":"2017","journal-title":"Crit Rev Oncog"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2020-206681","article-title":"Xp11 translocation renal cell carcinoma with morphological features mimicking multilocular cystic renal neoplasm of low malignant potential: a series of six cases with molecular analysis","volume":"74","author":"Song","year":"2021","journal-title":"J Clin Pathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2015.02.003","article-title":"MiT family translocation renal cell carcinoma","volume":"32","author":"Argani","year":"2015","journal-title":"Semin Diagn Pathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31827e17cb","article-title":"TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum","volume":"37","author":"Rao","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/biom9040131","article-title":"Splicing factors have an essential role in prostate cancer progression and androgen receptor signaling","volume":"9","author":"Takayama","year":"2019","journal-title":"Biomolecules"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23331","article-title":"Translocation renal cell carcinoma: lack of negative impact due to lymph node spread","volume":"112","author":"Geller","year":"2008","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3283","article-title":"Comprehensive genomic analysis of translocation renal cell carcinoma reveals copy-number variations as drivers of disease progression","volume":"26","author":"Marcon","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081110","article-title":"MiT family translocation renal cell carcinoma: from the early descriptions to the current knowledge","volume":"11","author":"Calio","year":"2019","journal-title":"Cancers"},{"key":"B36","doi-asserted-by":"publisher","first-page":"7494","DOI":"10.1038\/s41467-022-34460-w","article-title":"Proteogenomic characterization of MiT family translocation renal cell carcinoma","volume":"13","author":"Qu","year":"2022","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318293d872","article-title":"High chromosomal copy number alterations in Xp11 translocation renal cell carcinomas detected by array comparative genomic hybridization are associated with aggressive behavior","volume":"37","author":"Pan","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0475","article-title":"The clinical activity of PD-1\/PD-L1 inhibitors in metastatic non-clear cell renal cell carcinoma","volume":"6","author":"McKay","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s40425-018-0482-z","article-title":"Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders","volume":"6","author":"Boileve","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/11537220-000000000-00000","article-title":"Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma","volume":"30","author":"Hou","year":"2010","journal-title":"Clin Drug Investig"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1116648\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T05:05:28Z","timestamp":1675400728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1116648\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,3]]},"references-count":40,"alternative-id":["10.3389\/fonc.2023.1116648"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1116648","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,3]]},"article-number":"1116648"}}